Liver Cancer
Antiangiogenic gene therapy treats tumors in hepatocellular carcinoma models
Published in Hepatitis Weekly, May 23rd, 2005
"Hepatocellular carcinoma (HCC) is regarded as a suitable target for antiangiogenic strategies. However, antiangiogenic agents aimed at single targets can be neutralized by upregulation of other proangiogenic factors. Therefore, combined approaches addressing at least two angiogenic targets should be more effective," scientists writing in the journal Hepatology report.
"Employing an appropriate rat hepatoma model, we examined the effects of sFlt-1 (soluble vascular endothelial growth factor (VEGF) receptor 1 as an indirect inhibitor of angiogenesis) and endostatin (a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-05-23)
More Articles from Hepatitis Weekly
- Chronic Hepatitis C
Hepatitis C core antigen may prevent liver injury in infected patients - Gastroenterology
Primary human hepatocytes repopulate the livers of chimeric mice - Oncology
Aberrant proteins are a hallmark of primary liver cancer progression - Transplant Medicine
Ribavirin promotes liver fibrosis in HCV-positive kidney recipients - Virology
Viral interactions accelerate non-Hodgkin lymphoma progression - Addiction Medicine
Immunostains discern alcoholic steatohepatitis from nonalcoholic disease - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
